Invention Grant
- Patent Title: Heteroaryl carboxamide compound
-
Application No.: US18521400Application Date: 2023-11-28
-
Publication No.: US12077519B2Publication Date: 2024-09-03
- Inventor: Hideyuki Watanabe , Takashi Kamikubo , Akio Kamikawa , Takuya Washio , Yohei Seki , Keiichiro Okuyama , Osamu Ikeda , Hiroshi Tomiyama , Yoshinori Iwai , Akihiko Nakamura , Kozo Miyasaka
- Applicant: Astellas Pharma Inc. , Kotobuki Pharmaceutical Co., Ltd.
- Applicant Address: JP Tokyo
- Assignee: Astellas Pharma Inc.,KOTOBUKI PHARMACEUTICAL CO., LTD.
- Current Assignee: Astellas Pharma Inc.,KOTOBUKI PHARMACEUTICAL CO., LTD.
- Current Assignee Address: JP Tokyo; JP Nagano
- Agency: McCarter & English, LLP
- Agent Wei Song; James M. Alburger
- Priority: JP 20197899 2020.11.30
- Main IPC: C07D401/12
- IPC: C07D401/12 ; A61K31/454 ; A61K31/4545 ; A61K31/496 ; A61K31/501 ; A61K31/519 ; A61P35/00 ; C07D401/14 ; C07D403/12 ; C07D403/14 ; C07D405/14 ; C07D413/04 ; C07D413/14 ; C07D487/04
Abstract:
A compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy is provided.
The present inventors have conducted studies on a compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy, and confirmed that a heteroaryl carboxamide compound has DGK ξ (DGKzeta) inhibitory effect, leading to completion of the present invention. The heteroaryl carboxamide compound of the present invention has DGK ξ inhibitory effect, and can be used as a therapeutic agent for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy.
The present inventors have conducted studies on a compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy, and confirmed that a heteroaryl carboxamide compound has DGK ξ (DGKzeta) inhibitory effect, leading to completion of the present invention. The heteroaryl carboxamide compound of the present invention has DGK ξ inhibitory effect, and can be used as a therapeutic agent for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy.
Public/Granted literature
- US20240101532A1 HETEROARYL CARBOXAMIDE COMPOUND Public/Granted day:2024-03-28
Information query
